OCULAR THERAPEUTIX, INC Increase Decrease In Operating Lease Liability
OCULAR THERAPEUTIX, INC (OCUL) reported Increase Decrease In Operating Lease Liability of $956.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$812.00K, a 7481.82% decline year-over-year.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for the quarter ending 2026-03-31 was $1.77M.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$759.00K.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$642.00K.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for fiscal 2025 was -$1.65M.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for fiscal 2024 was -$1.19M.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for fiscal 2023 was -$1.81M, a 166.43% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC increase decrease in operating lease liability for fiscal 2022 was $2.73M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$812.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $956.00K 10-Q · filed 2026-08-03 | $197.00K derived: sum of 3 quarters · filed 2026-08-03 | -$445.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.77M 10-Q · filed 2026-05-05 | $1.01M derived: sum of 2 quarters · filed 2026-05-05 | $367.00K derived: sum of 3 quarters · filed 2026-05-05 | $378.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$1.40M derived: sum of 2 quarters · filed 2026-02-05 | -$1.39M derived: sum of 3 quarters · filed 2026-08-03 | -$1.65M 10-K · filed 2026-02-05 |
| 2025-09-30 | -$642.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$631.00K derived: sum of 2 quarters · filed 2026-08-03 | -$887.00K 10-Q · filed 2025-11-04 | -$918.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$245.00K 10-Q · filed 2026-08-03 | -$276.00K derived: sum of 3 quarters · filed 2026-08-03 | -$723.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$256.00K 10-Q · filed 2026-05-05 | -$287.00K derived: sum of 2 quarters · filed 2026-05-05 | -$734.00K derived: sum of 3 quarters · filed 2026-05-05 | -$927.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$478.00K derived: sum of 2 quarters · filed 2026-02-05 | -$671.00K derived: sum of 3 quarters · filed 2026-02-05 | -$1.19M 10-K · filed 2026-02-05 |
| 2024-09-30 | -$447.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$640.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.16M 10-Q · filed 2025-11-04 | -$1.82M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | -$193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$708.00K 10-Q · filed 2025-08-05 | -$1.37M derived: sum of 3 quarters · filed 2026-02-05 | -$1.65M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | -$515.00K 10-Q · filed 2025-05-05 | -$1.18M derived: sum of 2 quarters · filed 2026-02-05 | -$1.45M derived: sum of 3 quarters · filed 2026-02-05 | -$1.98M derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | -$665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$938.00K derived: sum of 2 quarters · filed 2026-02-05 | -$1.47M derived: sum of 3 quarters · filed 2026-02-05 | -$1.81M 10-K · filed 2026-02-05 |
| 2023-09-30 | -$273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$803.00K derived: sum of 2 quarters · filed 2024-11-14 | -$1.15M 10-Q · filed 2024-11-14 | $2.77M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$875.00K 10-Q · filed 2024-08-07 | $3.05M derived: sum of 3 quarters · filed 2025-03-03 | $2.63M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$345.00K 10-Q · filed 2024-05-07 | $3.58M derived: sum of 2 quarters · filed 2025-03-03 | $3.16M derived: sum of 3 quarters · filed 2025-03-03 | $2.76M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.51M derived: sum of 2 quarters · filed 2025-03-03 | $3.11M derived: sum of 3 quarters · filed 2025-03-03 | $2.73M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$416.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$814.00K derived: sum of 2 quarters · filed 2022-11-07 | -$1.19M 10-Q · filed 2022-11-07 | -$1.55M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | -$398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$778.00K 10-Q · filed 2022-08-08 | -$1.14M derived: sum of 3 quarters · filed 2024-03-11 | -$1.49M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | -$380.00K 10-Q · filed 2022-05-09 | -$741.00K derived: sum of 2 quarters · filed 2024-03-11 | -$1.09M derived: sum of 3 quarters · filed 2024-03-11 | -$1.42M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | -$361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$709.00K derived: sum of 2 quarters · filed 2024-03-11 | -$1.04M derived: sum of 3 quarters · filed 2024-03-11 | -$1.36M 10-K · filed 2024-03-11 |
| 2021-09-30 | -$348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$681.00K derived: sum of 2 quarters · filed 2022-11-07 | -$997.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$333.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$649.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$316.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$1.13M 10-K · filed 2023-03-06 | |||
| 2019-12-31 | -$844.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |